Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.
Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.
复制标题
雌激素受体阳性和 HER2 阴性乳腺癌中胶原凝胶液滴包埋培养药物敏感性测试和 Ki67 表达。
DOI：
10.3892/mco.2012.4
复制
发表时间：
2013
影响因子：
1.2
通讯作者：
I. Takeyoshi
中科院分区：
文献类型：
--
作者：
K. Tozuka;J. Horiguchi;D. Takata;N. Rokutanda;R. Nagaoka;H. Tokiniwa;M. Kikuchi;A. Satou;H. Takei;I. Takeyoshi
蒽环类药物和紫杉烷类药物是乳腺癌化疗中使用的标准抗癌药物。一般来说，与 ER 阴性肿瘤患者相比，雌激素受体 (ER) 阳性肿瘤患者的化疗疗效较低。尽管对化学敏感性较低，但 ER 阳性疾病包括一部分可从辅助化疗中显着受益的患者。胶原凝胶液滴包埋培养药物敏感性试验（CD-DST）是一种体外化学敏感性试验，与传统试验相比具有多种优点。本研究的目的是检查 CD-DST 与肿瘤增殖指标 Ki67 表达之间的相关性，以评估蒽环类药物和紫杉烷类药物对 ER 阳性和人表皮生长因子受体 2 (HER2) 阴性乳腺癌患者的疗效。 2001年8月至2006年11月，对68例ER阳性和HER2阴性乳腺癌患者进行了CD-DST。手术中获得的标本用于CD-DST和Ki67表达的免疫组织学检查。使用 CD-DST 评估抗癌药物阿霉素 (ADM)、表柔比星 (EPI)、多西他赛 (DOC) 和紫杉醇 (PTX) 的化学敏感性。 CD-DST结果显示，各抗癌药物的化疗敏感性为ADM，23.7%； EPI，75.0%； DOC，69.2%，PTX，43.6%。对DOC敏感组的Ki67表达显着高于对DOC（P=0.048）和PTX（P=0.036）耐药组。此外，>30% 的 Ki67 标记指数 (LI) 与 PTX 化学敏感性之间存在显着相关性。总之，从 CD-DST 和 Ki67 表达水平获得的结果能够识别出对化疗（特别是紫杉烷治疗）敏感的 ER 阳性和 HER2 阴性乳腺癌患者亚群。
Anthracyclines and taxanes are standard anticancer drugs used in breast cancer chemotherapy. In general, the efficacy of chemotherapy is lower in patients with estrogen receptor (ER)-positive tumors compared to patients with ER-negative tumors. Although less chemosensitive, ER-positive disease includes a subset of patients who significantly benefit from adjuvant chemotherapy. The collagen gel droplet-embedded culture-drug sensitivity test (CD-DST) is an in vitro chemosensitivity test that has several advantages over conventional tests. The aim of the present study was to examine the correlation between CD-DST and the expression of Ki67, an indicator of tumor proliferation, to evaluate the efficacy of anthracyclines and taxanes in patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. CD-DST was performed in 68 patients with ER-positive and HER2-negative breast cancer between August 2001 and November 2006. The specimens obtained during surgery were used for the CD-DST and immunohistological examination of Ki67 expression. Chemosensitivity to the anticancer drugs adriamycin (ADM), epirubicin (EPI), docetaxel (DOC) and paclitaxel (PTX) was estimated using CD-DST. Results obtained from the CD-DST showed the chemosensitivity to each anticancer drug to be ADM, 23.7%; EPI, 75.0%; DOC, 69.2% and PTX, 43.6%. Ki67 expression was significantly higher in the group that was sensitive to DOC compared to the group that was resistant to DOC (P=0.048) and PTX (P=0.036). In addition, a significant correlation was observed between a Ki67 labeling index (LI) of >30% and chemosensitivity to PTX. In conclusion, results obtained from CD-DST and Ki67 expression levels are able to identify a subset of patients with ER-positive and HER2-negative breast cancer who exhibit sensitivity to chemotherapy, particularly to taxane therapy.
登录
查看更多内容
影响因子：
45.3
作者：
Hugh, Judith;Hanson, John;Vogel, Charles
通讯作者：
Vogel, Charles
影响因子：
45.3
作者：
Henderson, IC;Berry, DA;Norton, L
通讯作者：
Norton, L
DOI：
--
发表时间：
1998-02
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
E. Mechetner;A. Kyshtoobayeva;S. Zonis;Hun-Gu Kim;R. Stroup;R. García;R. Parker;J. Fruehauf
通讯作者：
E. Mechetner;A. Kyshtoobayeva;S. Zonis;Hun-Gu Kim;R. Stroup;R. García;R. Parker;J. Fruehauf
影响因子：
158.5
作者：
Sparano, Joseph A.;Wang, Molin;Davidson, Nancy E.
通讯作者：
Davidson, Nancy E.
一项前瞻性随机试点研究，旨在评估局部晚期乳腺癌患者连续核心活检对单药新辅助阿霉素或紫杉醇反应的预测因素。
DOI：
--
发表时间：
2003
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research.
影响因子：
--
作者：
Stearns,Vered;Singh,Baljit;Tsangaris,Theodore;Crawford,JeanetteG;Novielli,Antonella;Ellis,MathewJ;Isaacs,Claudine;Pennanen,Marie;Tibery,Cecilia;Farhad,Ahmad;Slack,Rebecca;Hayes,DanielF
通讯作者：
Hayes,DanielF